Compare Bima Sakti Pertiwi Tbk. (PAMG) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bima Sakti Pertiwi Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Bima Sakti Pertiwi Tbk. trades at Rp56 (market cap 175B, 6.26M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Bima Sakti Pertiwi Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| PAMG | SCPI | |
|---|---|---|
Market Cap | 175B | 104.4B |
Volume | 6.26M | — |
Lot | 62.6K | — |
Turnover | 346.31M | — |
Average Price | 55.32 | — |
Value | 346.31M | — |
Indicative Equilibrium Price | 56 | — |
Indicative Equilibrium Volume | 2.3K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bima Sakti Pertiwi Tbk.
PT Bima Sakti Pertiwi Tbk (the Company) was established based on the Notarial Deed of Raden Minarno Hardjokoesoemo, S.H., Deputy Notary in Tanjungpinang, No. 30, dated April 28, 1980.
Read more on PAMG →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
